Embed Size (px)
Citation preview
LUTHERAN CANCER CENTER2017 REPORT | 2016 DATA
2
A MESSAGE FROM THE CEO
WE CAN
Paula AutryCEO, Lutheran Hospital
Hope provides optimism, determination and courage to take on a cancer diagnosis. Hope gives patients the confidence to become a fighter.
The physicians and staff of the Lutheran Cancer Center help give patients hope by providing comprehensive cancer services in a compassionate and caring environment. Patients know they are being cared for
by some of the best specialists in the region with the most high-tech treatment technologies available.
That knowledge gives cancer patients hope — and hope is everything.
The 2017 Lutheran Cancer Center’s annual report is an overview of the center’s services and highlights the commitment made by physicians and staff to care for and guide patients through one of life’s most challenging ordeals on each step of their journey, and to give them hope.
3
A WORD FROM THE CANCER COMMITTEE CO-CHAIRMEN
The Lutheran Cancer Center is recognized as a leader in the region for innovative and
effective cancer care. The center continues to grow and build on established strengths while
looking toward the future for new and innovative diagnostic tools and treatment options.
In 1991, Fort Wayne Medical Oncology and Hematology and Radiation Oncology Associates
began performing clinical trials and continue to participate in innovative clinical research.
In 2012, several new trials were added involving urothelial carcinoma, HER2+ breast cancer
and lung cancer trials. Now, 31 trials are active, making the Lutheran Cancer Center a top
innovator for cancer care.
In Oct. 2017, Fort Wayne Medical Oncology and Hematology opened the Inventa Center for
Cancer Research to continue the 25-year commitment to leading advanced research and
clinical trails in partnership with the top academic research programs from across the U.S.
It is our pleasure to continue to co-chair the Lutheran Cancer Committee. Our goal, which
is made evident in the pages of this report, is to continue to enhance the quality and
accessibility of comprehensive cancer care for patients throughout the region.
Steven Rhinehart, MD*
Fort Wayne Medical Oncology and Hematology
R. Prasad Mantravadi, MD*
Radiation Oncology Associates
Patients ring the Bell of Hope, which is located in the Cancer Resource Center’s garden, after completing a course of treatment, such as radiation therapy and/or chemotherapy. Ringing the bell symbolizes hope for the future for patients as cancer treatments end and the next phase of life begins.
0
1000
2000
3000
2012 2013 2014 2015 2016
2502
30542707
32473465
PALLIATIVE CARE: INPATIENT VOLUMES
4
THE LUTHERAN CANCER CENTER, part of Lutheran Hospital and the Lutheran Health Network,
is a 48,000 square-foot comprehensive cancer treatment facility located on the Lutheran Hospital campus. Medical
and radiation oncologists, surgeons and the entire cancer care team work together to deliver innovative and high-tech
cancer treatments while also caring for patients’ minds, bodies and spirits. This integrated approach not only gives
patients fast access to top-notch cancer care, it also lets them know the team is with them, helping them overcome
obstacles and fear with physical, educational and emotional support.
PALLIATIVE CAREPalliative care is specialized medical care for people with serious, life-limiting illnesses. The primary goal of palliative care
is to improve quality of life for both patients and families by relieving symptoms associated with the illness or treatment,
such as anxiety, constipation, dyspnea, fatigue, insomnia, loss of appetite, nausea and pain, as well as symptoms caused
by various medications. Palliative care can be provided with
curative or life-prolonging treatment and can be initiated at
any time during an illness. Unlike hospice care, palliative care
services are not dependent on a prognosis.
Palliative services are provided in both the inpatient and
outpatient setting by a care team that includes a palliative
care physician, certified palliative care nurses, nurse
practitioners, social workers, case managers and chaplains.
In addition to symptom management, the team helps
patients and families better understand the illness and its
future challenges, helps establish a current and long-term
plan of care based on patient goals and ensures appropriate
resources are available when needed.
Inside the Lutheran Cancer Center
} Breast Surgical Oncology
} Clinical Dietitian
} Fort Wayne Medical Oncology and Hematology*
} Genetic Counseling*
(collaboration with the Northeast Indiana Genetic Counseling Center)
} Lutheran Adult Outpatient Clinic
} Lutheran Cancer Registry
} Lutheran Cancer Resource Center
(a free service provided by Lutheran Hospital)
} Lutheran Children’s Hospital Outpatient Pediatric
Hematology/Oncology Clinic
(affiliated with Riley Hospital for Children, Indianapolis)
} Radiation Oncology Associates*
} Surgical Oncology
Services Accessible through the Lutheran Cancer Resource Center
} Case management/social services
} Dietary
} Home health and hospice
} Pastoral care
} Support groups/survivorship
Services Available by Referral
} American Cancer Society
} Cancer rehabilitation
} Cancer Services of Northeast Indiana
} Clinical trials
} Diagnostic (imaging and laboratory)
} Lymphedema management
} Palliative Care Clinic* (affiliated with Visiting Nurse)
5
NURSE NAVIGATORSFor more than a decade, Lutheran’s cancer navigators have helped thousands face the confusing and anxious days that
follow a cancer diagnosis. Navigators empower patients and their families with the knowledge they need to make the
choices that are right for them. The center’s nurse navigators include a certified breast care nurse and a lung cancer
screening navigator.
Navigator services include:
FREE RESOURCE
Lutheran Cancer Resource Center: (260) 435-7959 Lung Cancer Screening Hotline: (260) 435-7522
} Explaining treatment options
} Helping patients and their families understand
the cancer diagnosis
} Providing emotional support
} Helping patients schedule and navigate
through physician appointments
} Addressing psychosocial needs by connecting
patients with needed services such as financial
assistance, home health, nutrition counseling,
physical therapy and support groups
} Providing ongoing support after treatment
THE RESOURCE CENTER STAFF
(LEFT TO RIGHT)
Michelle Clabaugh, RN, OCNOncology-Certified Nurse
Barbara Gard, RN, MSN, CNS, OCN, CBCNOncology Clinical Nurse Specialist
Wendy Rowland, RN, BSN, OCNOncology-Certified Nurse
Executive Director of Oncology:
Linda Jordan, RN, BSN, MBA, OCNOncology-Certified Nurse
Christy Bethay, RN, BSNGI Navigator
Laura Clark, RN, BSN, CN-BNBreast Navigator
Hollie Painter, RN, CN-BNBreast Navigator
6
PHYSICIAN-LED PROGRAMS
Clinical Trials
Patients receiving treatment at the Lutheran Cancer Center have access
to clinical trials through collaboration with Fort Wayne Medical Oncology
and Hematology and Radiation Oncology Associates. Affiliated with Cancer
and Leukemia Group B, Southwest Oncology Group, Hoosier Oncology
Group, Radiation Therapy Oncology Group, UCLA and other national and
regional clinical research groups, these trials allow qualified patients to
receive innovative treatments without leaving the Fort Wayne area. Many of
these trials are landmark studies that have changed practice standards and
oncology guidelines.
Oncologists who practice at the Lutheran Cancer Center are some of the most
active specialists in the country for clinical trial enrollment. FWMOH has been
recognized by the American Society of Clinical Oncology as one of the top 10
community practices for clinical cancer trial enrollment in the United States.
Weekly Cancer Conference
A group of multispecialty physicians and clinical staff meet each Friday
to review the most challenging cancer cases. Patient histories, diagnostic
and pathological data, National Comprehensive Cancer Network guidelines
pertaining to each case and up-to-date results from scientific studies are
examined. These conferences provide an opportunity for physicians to discuss
treatment options and garner feedback from their colleagues and provide
patients the opportunity to have a team of physicians discuss their cases and
reach a consensus for the best treatment protocol. Recommendations are then
communicated to the treating physicians. Physicians interested in presenting a
case should contact the tumor registrar at (260) 435-7939.
Lutheran Cancer Committee
The Lutheran Cancer Committee meets quarterly to evaluate, plan, initiate
and implement cancer-related activities that enhance services and programs.
The committee sets ambitious goals that keep the entire program on the
leading edge of cancer care. The cancer committee consists of physicians from
various specialties and representatives from administration, cancer registry,
case management, education, hospice, marketing, nutrition services, oncology
nursing, pastoral care, pathology, pediatric oncology, pharmacy, quality,
radiology rehabilitation, research and social services as well as representatives
from the oncology community.
} Breast ..........................................185
} Colorectal .................................. 54
} Gastrointestinal ....................... 31
} Lymphoma .................................25
} CNS ............................................... 24
} Lung .............................................. 24
} Pancreas ...................................... 21
} Skin ................................................ 19
} Gynecologic .............................. 15
} Sarcoma....................................... 14
} Unknown .......................................9
} Other Ill-Defined Sites .......... 7
} Genitourinary .............................4
} Head and Neck .......................... 3
} Leukemia/blood disorders . 3
2016 CANCER CONFERENCES
SITE TOTAL CASES PRESENTED
Age
0–9
Age
10–1
9
Age
20–2
9
Age
30–3
9
Age
40–49
Age
50–59
Age
60–69
Age
70–7
9
Age
80–89
Age
90–99
0
Nu
mb
er
of
Pa
tie
nts
100
200
300
400
500
2012
2013
2014
2015
2016
7
(LEFT TO RIGHT)
Kimberly Cardin, RN, RHIT, CTRCertified Tumor Registrar
Peggy Downs, CTRCancer Registry Supervisor, Certified Tumor Registrar
Nicki LuginbillClerk
Jodi Landis, RHITTumor Registrar
Constance Barker, CTRCertified Tumor Registrar
CANCER REGISTRYThe Lutheran Cancer Registry collects and reports data about cancer and tumor disease to the Indiana State
Department of Health and the National Cancer Data Base. Data is collected by certified cancer registrars. Registrars
capture a complete summary of patient history, diagnosis, treatment and status for every cancer patient diagnosed
or treated at the Lutheran Cancer Center.
The registry staff also coordinates the weekly cancer conference and is responsible for helping to maintain the
certification of a Community Hospital Comprehensive Cancer Program with the American College of Surgeons
Commission on Cancer.
Since 2004, the year the hospital began submitting data to the National Cancer Data Base, the Lutheran cancer
registry team has abstracted a total of 20,823 diagnoses of cancer. Since the registry’s inception in the late 1980s,
the registry team has reported 36,434 incidents of cancer. The registry team is also charged with following patients
for their lifetime and reporting any incident of recurrence. The registry currently exceeds the mandated 90 percent
lifetime follow-up rate.
AGE AT DIAGNOSIS, 2012 – 2016
CANCER REGISTRARS
2
9
16
23
30
1
8
15
22
29
6
13
20
27
3
10
17
24
31
4
11
18
25
5
12
19
26
8
THE PEOPLE MAKE THE DIFFERENCEMeet a few of the specialists, who along with hundreds of other physicians, nurses and staff members,
devote themselves to treating patients at the Lutheran Cancer Center.
7
14
21
28
9
± 1 Neal Agee, MDLutheran Medical Group
± 2 Lubna Ahmed, MDLutheran Children’s Hospital, Lutheran Health Physicians
3 Charles Aust, MD*
PathGroup
4 Sunil Babu, MD*
Fort Wayne Medical Oncology and Hematology
± 5 Patricia Bader, MD*
Northeast Indiana Genetic Counseling
6 Matthew L. Carr, MD*
Fort Wayne Medical Oncology and Hematology
7 Nathan Comsia, MD*
Radiation Oncology Associates
8 Christopher Dempsher, MD*
PathGroup
± 9 Nadine Floyd, MD*
Center for Colon & Rectal Care
10 Ryan Gonzales, MD*
Fort Wayne Medical Oncology and Hematology
± 11 Rachael Hayes, MDLutheran Health Physicians
12 Eric V. Heatwole, MD*
Summit Radiology
± 13 Praveen Kollipara, MD*
Fort Wayne Medical Oncology and Hematology
14 Xiao Lin, MD*
Radiation Oncology Associates
15 David Lippie, MDLutheran Health Physicians
± 16 R. Prasad Mantravadi, MD, FACR, FACRO*
Radiation Oncology Associates
± 17 Ann M. Moore, DO, FACCOI, CMD*
Visiting Nurse
18 Yasolatha Nalamolu, MD*
Fort Wayne Medical Oncology and Hematology
19 Sreenivasa R. Nattam, MD*
Fort Wayne Medical Oncology and Hematology
± 20 Dennis O’Brien Jr., MDLutheran Children’s Hospital, Lutheran Health Physicians
21 Dolly R. Quispe, MD*
Fort Wayne Medical Oncology and Hematology
22 Mark C. Ranck, MD*
Radiation Oncology Associates
23 Donald N. Reed Jr., MD, FACSLutheran Health Physicians
± 24 Steven N. Rhinehart, MD*
Fort Wayne Medical Oncology and Hematology
± 25 Rich Sibley, MD*
Summit Radiology
26 Bryon Stephens, MDLutheran Health Physicians
27 David B. Tribble, MDVisiting Nurse
28 Mary Wilger, DO*
Visiting Nurse
±29 Peter Wu, MD*
PathGroup
30 Gerald Yancey, MD*
PathGroup
31 David Zimmerman, MD*
Fort Wayne Medical Oncology and Hematology
± Denotes Lutheran Cancer Committee member
Not pictured:Saad Ibrahim, MD, Summit RadiologyAshwini Pandit, MD, PathGroupIan White, MD, NeuroSpine & Pain Center
AGE
CO
NC
ER
NS
10
Study Topic: To identify the types of problems causing distress for the acute leukemia patient admitted to the
hospital for induction treatment. Distress screening is a recommended component of comprehensive cancer care,
but the severity and sources of distress among patients with acute myeloid leukemia are unknown.
National Guideline: NCCN Clinical Practice Guideline in Oncology for Distress Management outlines the standard
of care for distress management.
} Distress should be recognized, monitored, documented and treated promptly at all stages
of disease and in all settings.
} Ideally, patients should be screened for distress at every medical visit as a hallmark of
patient-centered care. At a minimum, patients should be screened for distress at their initial
visit, at appropriate intervals and as clinically indicated, especially with changes in disease
status (i.e. remission, recurrence, progression, treatment-related complications).
} Clinical health outcomes measurement should include assessment of psychosocial domain
(e.g. quality of life and patient and family satisfaction).
Methods: Patients admitted with a new diagnosis of acute leukemia for induction chemotherapy were asked
to identify their concerns in regards to their diagnosis and knowing their hospital stay will span over weeks.
The 39-item Problem List of the NCCN Distress Management Tool was utilized prior to receiving their induction
chemotherapy. The list has five categories: Practical Problems, Family Problems, Emotional Problems, Spiritual/
Religious Concerns and Physical Problems.
Results: Eight patients ranging in age from 32–79 years old identified the following concerns:
} Most important areas of concerns by all eight patients:
Insurance/Financial, Treatment Decisions, Fears, Worry,
Fatigue and Sleep
} Least areas of concerns identified: Dealing with Partner,
Loss of Interest in Usual Activities, Constipation, Memory/
Concentration, Substance Abuse and Tingling in Hands
and Feet
} 20 out of 39 areas of concerns or 51% were identified by
the youngest patient
} 13 out of 39 areas of concerns or 31% were identified by the 50–64 year old patients
} 9 out of 39 areas of concerns or 23% were identified by the oldest patient
Action Plan: This study demonstrates the concerns of our cancer patients when faced with a long admission in
the hospital and the need to expedite consults to the appropriate departments as identified.
2016 QUALITY STUDY #1
Reference: NCCN Guidelines Version 1.2017 Distress Management www.nccn.org
11
2016 QUALITY STUDY #2
Study Topic: To conduct a literature search to evaluate the documented benefits of music therapy for cancer patients.
National Benchmarks:
} The National Comprehensive Cancer Network Guideline for Distress Management panel
recommends relaxation, meditation and creative therapies such as art and music for patients
experiencing distress.
} The National Comprehensive Cancer Network Guideline for Cancer-Related Fatigue
recommends music therapy as a distraction strategy for general management of fatigue.
Results: While music therapy does not actually affect the disease itself, it has a great impact on the cancer patient’s
social, physical and emotional well-being (Stanczyk, 2011). The American Music Therapy Association establishes
criteria for the education and clinical training of music therapists. Members of the AMTA adhere to a Code of Ethics
and Standards of Practice in their delivery of music therapy services. Quality of Life of terminally ill cancer patients
using the Hospice Quality of Life Index-Revised, a self-report measure, found quality of life was higher for patients
receiving music therapy than the patients who did not receive music therapy sessions (Hilliard, 2003).
The music therapist provides opportunities for anxiety and stress reduction, nonpharmacological management of
pain and discomfort, relaxation for patient and caregivers, active and positive patient participation in treatment
and some physiological changes such as lower blood pressure, reduce heart rate and relaxed muscles.
Action: Results from multiple studies and NCCN Guidelines demonstrated the effectiveness of music therapy with
oncology patients as they go through their cancer treatment and end-of-life care.
References:
www.nccnguidelines.com
www.musictherapy.org
www.utswmedicine.org
Stanczyk, M.M., (2011) Music therapy in supportive cancer care. Reports of Practical Oncology and Radiotherapy, 16, 170–172.
Bradt, J., et.al., (2015) The Impact of music therapy versus music medicine on psychological outcomes and pain in cancer patients: a mixed methods
study. Support Care Cancer 23: 1261–1271.
Bailey, L. M., (1984) The use of songs in music therapy with cancer patients and their families. Music Therapy, Vol. 4 No. 1, 5–17.
Hilliard, R.E., (2003) The effects of music therapy on the quality and length of life of people diagnosed with terminal cancer. J Music Ther 40(2): 113–137.
12
QUALITY IMPROVEMENT TOPIC 1
To keep oncology patients on the oncology unit instead of being transferred to another unit for cardiac monitoring.
The oncology unit is staffed with oncology nurses who are familiar with the patient’s treatment, family dynamics
and standard of care.
Goal of the Quality Improvement
To submit a request to administration for the purchase of 4–6 external cardiac monitors for the oncology unit.
In addition to the acquisition of the heart monitors, staff education will need to be planned and implemented for
reading the monitors by the education department.
Process Change
Despite the continuous improvements in the management of cancer, cardiac side effects still represent a substantial
drawback of chemotherapy. Multiple drug protocols, combination regimens and adjuvant and targeted therapies
administered to patients in increased numbers have resulted in prognosis and survival improvements. However,
administration of some cytotoxic agents and/or targeted therapies may result in several cardiac complications
such as left ventricular dysfunction, heart failure, myocardial ischemia, arrhythmias and conduction abnormalities
depending on the drug or regimen the patient is receiving. At the present time, the oncology patient is evaluated for
cardiac abnormalities and transferred to either a telemetry unit or the intensive care unit dependent on the patient’s
condition. Acquiring the cardiac monitors along with staff education could prevent the oncology patients from
leaving the oncology unit.
Quantifiable Improvements
Oncology 2A received six portable telemonitors. A mandatory online ALC (Advanced Learning Center) educational
program about EKGs was launched for all RNs on the oncology unit. An EKG breakfast and lunch educational meeting
was presented by the education department. Reference cards along with a review of the EKG strips were provided.
QUALITY IMPROVEMENTS
The Lutheran Hospital Cancer Committee reviewed, discussed and implemented two quality improvement initiatives
to enhance patient care.
13
QUALITY IMPROVEMENT TOPIC 2
To initiate music therapy for adult oncology patients admitted to Oncology 2A.
Goal of the Quality Improvement
The National Comprehensive Cancer Network Guideline for Distress Management and Cancer-Related Fatigue
recommend music therapy as a complementary supportive care treatment. Studies have demonstrated the
psychological and physical benefits of music therapy to cancer patients and their significant others.
Process Change
At the present time, music therapy is offered to the pediatric patient population. Lutheran Hospital employs a
board-certified music therapist. Music therapy services are available to patients at no cost and may be requested by
patients, family members, physicians or staff. Nursing education will need to be planned and informational material
will need to be available for patients to request this service. Unit meetings are in the planning process to start the
education of staff and the process to request a music therapy consult.
Quantifiable Improvements
As a new process for the oncology unit, monitoring was ongoing throughout the year and a meeting was held with
Kim Lloyd, MA, MT-BC, music therapist. Brochures were obtained for her services explaining the benefits of music
therapy, the clinical and evidence-based aspect of therapeutic approaches to promote health, how to get started and
what to expect once a consult has been requested. The brochures are available to Oncology 2A patients and staff.
We presented the music therapy brochure to the Service Excellence Committee members and distributed the
brochures to patients at time of admission to help initiate consults. Music therapy process was discussed with all
questions answered at the Cancer Committee.
Follow-up Steps to Monitor Implementation
Future recommendations include developing a patient specific educational notebook with the brochure and benefits
of music therapy for cancer patients. The oncology unit manager will be working with administration and marketing
for development of this patient tool to help increase music therapy referrals and promote patient specific education.
14
PRIMARY SITE TABLE — 2016 DATA
* Excluding basal and squamous cell carcinoma
Buccal cavity and pharynx 3.9% 2 12 36 4 10 53 3 8 44 20
Lip 0.1% 1 0 1 0 0 2 0 0 2 0
Tongue 1.4% 0 2 17 0 4 21 1 1 18 5
Major salivary gland 0.3% 0 2 1 0 2 3 2 0 2 3
Floor of mouth 0.1% 0 0 1 1 0 1 0 1 2 0
Gum and other mouth 0.6% 1 1 2 1 4 6 0 3 2 7
Nasopharynx 0.1% 0 0 2 0 0 1 0 1 2 0
Tonsil 0.9% 0 3 9 2 0 14 0 0 12 2
Oropharynx 0.2% 0 1 2 0 0 3 0 0 1 2
Hypopharynx 0.1% 0 1 1 0 0 1 0 1 2 0
Other buccal cavity 0.1% 0 2 0 0 0 1 0 1 1 1
Digestive system 20.9% 5 83 138 92 22 319 18 3 194 146
Esophagus 1.9% 0 10 13 7 1 30 1 0 26 5
Stomach 1.2% 0 8 5 6 1 18 2 0 12 8
Small intestine 0.9% 0 4 5 5 1 15 0 0 6 9
Colon, excluding rectum 6.7% 1 26 53 19 10 100 6 3 57 52
Rectum and rectosigmoid 3.4% 2 9 33 7 4 50 5 0 29 26
Anus, anal canal, anorectal 0.4% 2 3 0 1 1 7 0 0 2 5
Liver 1.0% 0 6 6 2 2 14 2 0 12 4
Gallbladder 0.3% 0 0 0 5 0 5 0 0 2 3
Other biliary 0.4% 0 3 2 2 0 7 0 0 5 2
Pancreas 4.4% 0 14 21 36 1 70 2 0 42 30
Retroperitoneum 0.0% 0 0 0 0 0 0 0 0 0 0
Peritoneum 0.0% 0 0 0 0 0 0 0 0 0 0
Other digestive organs 0.2% 0 0 0 2 1 3 0 0 1 2
Respiratory system 17.9% 0 75 81 128 8 274 17 1 167 125
Nasal cavity sinuses 0.2% 0 3 0 1 0 4 0 0 3 1
Larynx 1.3% 0 12 7 1 1 19 2 0 15 6
Lung and bronchus 16.4% 0 60 74 126 7 251 15 1 149 118
Trachea pleura and other 0.0% 0 0 0 0 0 0 0 0 0 0
Bones and joints 0.2% 0 2 1 0 0 2 0 1 2 1
Soft tissue (including heart) 0.5% 0 5 3 0 0 7 0 1 7 1
Skin* 9.0% 26 57 8 6 50 138 1 8 85 62
Melanomas of the skin 8.8% 26 56 7 5 49 134 1 8 82 61
Other skin cancers 0.2% 0 1 1 1 1 4 0 0 3 1
Breast 13.8% 18 137 45 11 14 211 10 4 1 224
Female genital system 5.6% 10 44 17 14 6 87 3 1 0 91
Cervix uteri 0.9% 0 6 4 4 1 15 0 0 0 15
Corpus uteri 2.1% 0 26 6 0 2 32 2 0 0 34
Uterus NOS 0.2% 0 0 1 1 1 2 1 0 0 3
Ovary 1.5% 0 7 6 9 2 23 0 1 0 24
Vagina 0.1% 1 1 0 0 0 2 0 0 0 2
Vulva 0.8% 9 4 0 0 0 13 0 0 0 13
Other female genital organs 0.0% 0 0 0 0 0 0 0 0 0 0
SITE % of TOTAL CASES STAGE RACE SEX
I L R D U W B OTHER M F
15
Note: sites listed in orange are Lutheran's top five sites.
TOP CANCER SITES: MALE
} Lung and bronchus ................................149 (18.2%)
} Melanoma ......................................................82 (10.0%)
} Prostate gland ............................................ 73 (8.9%)
} Colon (excluding rectum) .................... 57 (6.9%)
} Kidney .............................................................56 (6.8%)
} Breast ............................................................ 224 (27.7%)
} Lung and bronchus ................................. 118 (14.6%)
} Melanoma .......................................................61 (7.5%)
} Colon (excluding rectum) .................... 52 (6.4%)
} Corpus uteri .................................................34 (4.2%)
SITE SITETOTAL CASES PRESENTED TOTAL CASES PRESENTED
Source: 2016 Lutheran Hospital Cancer Registry
TOP CANCER SITES: FEMALE
SITE % of TOTAL CASES STAGE RACE SEX
I L R D U W B OTHER M F
Male genital system 5.0% 0 43 18 12 9 73 8 1 82 0
Prostate gland 4.5% 0 39 16 9 9 64 8 1 73 0
Testis 0.4% 0 2 1 3 0 6 0 0 6 0
Penis 0.1% 0 2 0 0 0 2 0 0 2 0
Other male genital organ 0.1% 0 0 1 0 0 1 0 0 1 0
Urinary system 8.9% 31 90 8 12 4 134 10 1 108 37
Urinary bladder 3.5% 31 22 1 1 2 56 1 0 47 10
Kidney and renal pelvis 5.1% 0 66 4 11 2 73 9 1 56 27
Ureter 0.2% 0 2 2 0 0 4 0 0 4 0
Other urinary organs 0.1% 0 0 1 0 0 1 0 0 1 0
Eye 0.2% 1 2 0 0 1 4 0 0 2 2
Brain and other nervous system 1.7% 0 13 7 2 6 28 0 0 19 9
Brain 1.6% 0 12 7 1 6 26 0 0 18 8
Other nervous system 0.1% 0 1 0 1 0 2 0 0 1 1
Endocrine system 1.7% 0 15 11 1 1 27 1 0 8 20
Thyroid gland 1.7% 0 14 11 1 1 27 0 0 7 20
Other endocrine 0.1% 0 1 0 0 0 0 1 0 1 0
Lymphomas 5.2% 0 21 24 31 9 78 6 1 49 36
Hodgkin's disease 0.6% 0 1 5 4 0 10 0 0 5 5
Non-Hodgkin's lymphomas 4.6% 0 20 19 27 9 68 6 1 44 31
Multiple myeloma 1.7% 0 5 0 22 0 24 3 0 17 10
Leukemias 2.1% 0 0 1 33 0 33 1 0 21 13
Acute lymphocytic 0.4% 0 0 1 6 0 7 0 0 4 3
Chronic lymphocytic 0.3% 0 0 0 5 0 5 0 0 2 3
Acute myeloid 0.8% 0 0 0 13 0 13 0 0 9 4
Chronic myeloid 0.2% 0 0 0 3 0 2 1 0 3 0
Other leukemias 0.4% 0 0 0 6 0 6 0 0 3 3
Other ill-defined and unknown 1.5% 0 1 0 2 22 24 0 1 14 11
Cervix insitu 0.0% 0 0 0 0 0 0 0 0 0 0
I = Insitu D = Distant W = White M = Male
L = Local U = Unknown B = Black F = Female
R = RegionalKEY
2012
2013
2014
2015
2016
Digestive
Respiratory
Breast
Urinary
Genital, Male
Skin
Lymphoma
Head and Neck
Genital, Female
Endocrine
Leukemia
Brain
0 50 100 150 200 250 300 350
16
CANCERS TREATED, 2012 – 2016
2012 2013 2014 2015 2016
Brain 33 23 35 15 28
Leukemia 43 35 32 34 34
Endocrine 68 59 60 40 28
Genital, Female 68 82 63 74 91
Head and Neck 110 68 49 71 84
Lymphoma 101 80 85 90 85
Skin 70 73 76 87 147
Genital, Male 124 93 77 88 81
Urinary 143 133 130 124 145
Breast 193 156 155 161 225
Respiratory 271 276 257 311 267
Digestive 333 337 316 305 340
White African American Other
1600
1400
1200
1000
800
600
400
200
02015
1366
8730
2016
1516
8131
2012
1555
59 21
2013
1391
68 37
2014
1295
66 31
Male Female
800
700
600
500
400
300
200
100
0
751 732
2015
820 808
2016
835800
2012
777719
2013
726666
2014
17
GENDER DISTRIBUTION, 2012 – 2016
RACE AND ETHNICITY, 2012 – 2016
0 10094.2 %n = 17
0 10091.2 %n = 45
0 100100 %n = 1
0 100n = 5
100 %
0 10094.9 %n = 98
0 10097.6 %n = 82
18Source: 2017 National Cancer Data Base. Accessed Sept. 26, 2017.
RAPID QUALITY REPORTING SYSTEM (RQRS)
Breast Conserving SurgeryRadiation therapy is administered within one year
(365 days) of diagnosis for women under age 70
receiving breast conserving surgery for breast cancer.
Hormone TherapyTamoxifen or third generation aromatase inhibitor is
considered or administered within one year (365 days)
of diagnosis for women with AJCC T1 cN0M0, or stage
IB–III hormone receptor positive breast cancer.
Combination ChemotherapyCombination chemotherapy is considered or
administered within 4 months (120 days) of diagnosis
for women under 70 with AJCC T1cN0M0, or stage
IB–III hormone receptor negative breast cancer.
Radiation TherapyRadiation therapy is recommended or administered
following any mastectomy within one year (365 days)
of diagnosis of breast cancer for women with ≥4
positive regional lymph nodes.
Regional Lymph NodesAt least 12 regional lymph nodes are removed and
pathologically examined for resected colon cancer.
Adjuvant ChemotherapyAdjuvant chemotherapy is considered or administered
within four months (120 days) of diagnosis for
patients under the age of 80 with AJCC Stage III
(lymph node positive) colon cancer.
BC
SR
TH
TM
AC
MA
ST
RT
12R
LN
AC
T
Lutheran Hospital
State of Indiana
96.7 %
98 %
83.3 %
100 %
84.3 %
84.6 %
95.3 %
95.3 %
95.2 %
89.6 %
92.3 %
91.4 %
19
BC
SR
TH
TM
AC
MA
ST
RT
12R
LN
AC
T
RQRS: COMPARISON WITH OTHER PROGRAMS IN INDIANA
This page compares Rapid Quality
Reporting System (RQRS) data of
Lutheran Hospital with 46 other
accredited cancer programs in the
State of Indiana. This chart is based
on 2015 data, the most recent year
with complete data submitted to
RQRS.
ACCREDITED PROGRAM
Joint Commission accreditation and certification is
recognized nationwide as a symbol of quality that
reflects an organizations commitment to meeting
certain performance standards.
Lutheran Hospital has received CoC
accreditation with the Outstanding
Achievement Award for four consecutive
survey cycles (2007, 2010, 2013, 2016).
7910 W. Jefferson Blvd. | Fort Wayne, IN 46804
LutheranHealth.net/cancer
LUTHERAN CANCER CENTER
Lutheran Hospital is owned in part by physicians.
* Independent members of the medical staff of Lutheran Hospital.
For more information or to refer a patient, call:
(260) 435-7959
